Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,411 across all filing types
Latest filing 2021-01-25 Regulatory Filings
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
CALQUENCE MET PRIMARY EFFICACY ENDPOINT IN HEAD-TO-HEAD TRIAL AGAINST IBRUTINIB
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed with the SEC by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. It provides detailed information about clinical trial results for Calquence in a Phase III trial against ibrutinib in chronic lymphocytic leukemia. The document includes scientific and clinical data, trial design, endpoints, and company background. It is not an annual or quarterly report, nor is it an earnings release or a management discussion. It is a regulatory filing used by foreign companies to report material information to the SEC between annual reports. The document is not a certification or attestation, nor is it a proxy or voting result announcement. Given the nature of Form 6-K filings, this document fits best under Regulatory Filings (RNS) as it is a general regulatory announcement and does not fit other more specific categories.
2021-01-25 English
Calquence approved in Japan for CLL
Earnings Release Classification · 99% confidence The document begins with an 'RNS Number' and a date, indicating it is a regulatory announcement disseminated via the RNS service of the London Stock Exchange. The content details a specific corporate event: the approval of the drug Calquence in Japan for a specific medical condition. This type of announcement, which is a material update about product/market development rather than a full financial report (like 10-K or IR) or a transcript, fits best under the general category for regulatory announcements that do not fit other specific categories. Since it is a formal announcement of a significant event (drug approval) released through the official regulatory news service (RNS), it is classified as a Regulatory Filing (RNS). It is not an Earnings Release (ER), Interim Report (IR), or a specific legal/capital/management update, making RNS the most appropriate fallback/general regulatory category. Q1 2021
2021-01-25 English
Calquence met primary endpoint against ibrutinib
Regulatory Filings Classification · 99% confidence The document begins with 'RNS Number : 7284M' and is dated '25 January 2021 07:00 GMT'. It contains a headline about clinical trial results ('Calquence met primary efficacy endpoint...') and concludes with boilerplate text stating, 'This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.' This structure is characteristic of a regulatory news service announcement, which falls under the general category of Regulatory Filings (RNS), as it is an immediate, non-periodic disclosure of material information.
2021-01-25 English
ENHERTU APPROVED IN THE EU FOR BREAST CANCER
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. It contains detailed information about the approval of Enhertu in the EU for breast cancer, including clinical trial data, regulatory approvals, financial considerations, and company background. The document is not an annual or quarterly report, nor is it a transcript, audit report, or management change announcement. It is a regulatory filing providing material information about a significant event (drug approval) relevant to investors and the market. The length (15,000 characters) and content indicate it is a substantive report rather than a brief announcement or certification. Therefore, the appropriate classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2021-01-20 English
Enhertu approved in the EU for breast cancer
Regulatory Filings Classification · 99% confidence The document is clearly identified as originating from 'RNS Number : 2821M' and is dated '20 January 2021'. RNS stands for Regulatory News Service, which is the primary mechanism for listed companies in the UK (like AstraZeneca PLC) to disseminate regulatory information to the market. The content is a press release announcing the conditional approval of a drug (Enhertu) in the EU, including clinical trial data and financial considerations related to the approval. This type of broad, immediate regulatory announcement that doesn't fit neatly into specific financial reporting categories (like 10-K, ER, or DIV) is best classified as a general Regulatory Filing or Regulatory News Service announcement. Since 'RNS' is provided as a specific code for general regulatory announcements, it is the most appropriate classification, especially given the RNS header and footer.
2021-01-20 English
ENHERTU APPROVED IN THE US FOR GASTRIC CANCER
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed with the SEC by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. The content focuses on the announcement of the FDA approval of Enhertu for gastric cancer treatment, including clinical trial results, drug development, and financial considerations related to milestone payments. There are no detailed financial statements or comprehensive financial performance data typical of annual or interim reports. The document is an announcement of significant corporate news related to product approval and collaboration milestones rather than a full financial report or earnings release. Form 6-K filings are generally considered Regulatory Filings (RNS) as they provide material information from foreign issuers but do not fit into other specific categories like Annual Report or Earnings Release. Therefore, the appropriate classification is Regulatory Filings (RNS).
2021-01-19 English

Browse filings by year

34 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.